Aurobindo Pharma Ltd.'s profit in the quarter ended June missed analysts estimates.
Net profit fell 12.1 percent from the year-ago period to Rs 456 crore, the drugmaker said in its exchange filing. That compares with Rs 533-crore consensus estimate by analysts tracked by Bloomberg.
The company's revenue rose 15.5 percent year-on-year to Rs 4,250 crore in the June quarter. That's marginally higher than Rs 4,080 crore estimated. Earnings before interest, tax, depreciation and amortisation fell 7.4 percent from last year to 779 crore. Operating margin contracted 460 basis points to 18.3 percent in the April-June period.
The Hyderabad-based company's stock closed 1.72 percent lower on BSE at Rs 600.9 a piece ahead of the results' announcement.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
